Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada
Eris Lifesciences has reported total income of Rs. 403.80 crores during the period ended March 31, 2023
This latest audit re-emphasizes Hikal's commitment towards maintaining the best in class quality, compliance and regulatory standards across our manufacturing sites
He has over two decades of leadership experience as an innovative strategic planner in finance diligence
The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year
UAB Medexy's first order under the Distribution Agreement is for over 5000 units of SHIR and RELIEF&GO products
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
Subscribe To Our Newsletter & Stay Updated
